JERSEY CITY, N.J., Nov. 16, 2017 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
anti-infective therapies for difficult-to-treat and often
life-threatening infections, today announced the appointment of
Scott Sukenick, J.D., as General
Counsel, effective November 15, 2017.
Mr. Sukenick will be responsible for leading the Company's
corporate strategic and tactical legal initiatives, including
intellectual property and compliance. Mr. Sukenick will report to
Marco Taglietti, M.D., SCYNEXIS'
President and Chief Executive Officer.
"Scott brings invaluable legal and strategic expertise to
SCYNEXIS as we continue to advance our lead asset, SCY-078, through
clinical development," said Marco
Taglietti, M.D., SCYNEXIS' President and Chief Executive
Officer. "We are fortunate to have someone of his caliber, with a
combination of strong scientific acumen and a broad range of legal
experience in the life sciences sector. I welcome Scott to our
wonderful and dynamic team and look forward to our collaboration
with him to make SCYNEXIS a success."
Mr. Sukenick joins SCYNEXIS after over a decade addressing a
diversity of legal challenges faced by innovative life sciences
companies at all stages of development. Mr. Sukenick most recently
worked at Cooley LLP, where he focused on life sciences litigation
and strategic intellectual property management. Prior to that, he
worked at Patterson Belknap Webb & Tyler LLP, where he
primarily represented pharmaceutical and medical device companies
in patent litigation. He started his career at Simpson Thacher
& Bartlett LLP, where his practice focused on complex
commercial litigation and intellectual property transactional
matters. Mr. Sukenick is a registered patent attorney. He obtained
a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.
In connection with this appointment, on November 15, 2017, Mr. Sukenick was granted an
option to purchase 160,000 shares of SCYNEXIS common stock, at a
per share exercise price of $1.75,
the closing trading price on November 15,
2017. The option has a ten-year term, with one-fourth of the
shares subject to the option vesting on the one-year anniversary of
the date of grant and the remainder vesting in equal monthly
installments for thirty-six months thereafter, provided Mr.
Sukenick continues to provide service to SCYNEXIS. The stock option
was granted pursuant to SCYNEXIS' 2015 Inducement Award Plan, which
was adopted by the company's board of directors in March 2015 under Rule 5635(c)(4) of the Nasdaq
Global Market for equity grants to induce new employees to enter
into employment with the Company.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to
positively impacting the lives of patients suffering from
difficult-to-treat and often life-threatening infections by
delivering innovative anti-infective therapies. The SCYNEXIS team
has extensive experience in the life sciences industry, discovering
and developing more than 30 innovative medicines over a broad range
of therapeutic areas. The Company's lead product candidate,
SCY-078, is the first representative of a novel oral and IV
triterpenoid antifungal family and is in Phase 2 clinical
development for the treatment of several fungal infections,
including serious and life-threatening invasive fungal infections.
For more information, visit www.scynexis.com.
CONTACT
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com
Investor Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-appoints-scott-sukenick-as-general-counsel-300558258.html
SOURCE SCYNEXIS, Inc.